我国大肠癌患者平均5年生存率仅为40%左右,而欧美发达国家高达61%。10月23日在上海市召开的第四届中美大肠癌多学科综合治疗研讨会给出的答案是:不规范治疗是导致中国大肠癌生存率低的重要原因,其中包括可能近20%无需接受化疗的患者进行化疗,既增加治疗费用,又影响患者生存质量。以结直肠癌术后且无淋巴结转移患者的治疗为例,对患者是否进行化疗,化疗前的错配修复基因免疫组化检 The average 5-year survival rate of patients with colorectal cancer in China is only about 40%, while the developed countries in Europe and the United States up to 61%. The 4th symposium on multidisciplinary multi-disciplinary treatment of colorectal cancer in Shanghai on October 23 gave the answer that non-standard treatment is an important reason for the low survival rate of colorectal cancer in China, including possibly nearly 20% Chemotherapy in patients receiving chemotherapy, both to increase the cost of treatment, but also affect the quality of life of patients. In patients with colorectal cancer after surgery and without lymph node metastasis as an example, whether the patients with chemotherapy, chemotherapy before mismatch repair gene immunohistochemistry